Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00006478 · ClinicalTrials.gov registry record · Phase 2

Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma

A Phase 2 study, sponsored by University of Nebraska.

Terminated
Registry status
Phase 2
Development phase
19
Enrollment target

NCT00006478 is a Phase 2 study that was terminated before completion, run by University of Nebraska. The registered enrollment target is 19 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00006478, a Phase 2 study, was terminated before completion, sponsored by University of Nebraska.

TERMINATED
Registry status
Phase 2
Development phase
19 participants
Enrollment target

Study Summary

RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill cancer cells. Vaccine therapy may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy following chemotherapy and peripheral stem cell transplantation in treating patients who have non-Hodgkin's lymphoma.

Interventions

  • PROCEDURE adjuvant therapy
  • BIOLOGICAL sargramostim
  • BIOLOGICAL autologous tumor cell vaccine
  • BIOLOGICAL keyhole limpet hemocyanin

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2000-10-11
Est. Completion 2008-04-03
Phase Phase 2

Sponsor

University of Nebraska

407 total trials

What the Registry Record Tells You About NCT00006478

The ClinicalTrials.gov registry entry for NCT00006478 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which adjuvant therapy is the first listed.

NCT00006478 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00006478 about?

NCT00006478 is a clinical study titled "Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma". RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill cancer cells. Vaccine therapy may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy following chemotherapy and periphera...

What is the current status of trial NCT00006478?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2000-10-11. Estimated completion is 2008-04-03.

What interventions are being tested in trial NCT00006478?

The interventions under investigation include: adjuvant therapy (PROCEDURE), sargramostim (BIOLOGICAL), autologous tumor cell vaccine (BIOLOGICAL), keyhole limpet hemocyanin (BIOLOGICAL).

Who is sponsoring clinical trial NCT00006478?

This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.